Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Non-Current Assets (2016 - 2025)

Ptc Therapeutics has reported Non-Current Assets over the past 14 years, most recently at $624.8 million for Q4 2025.

  • Quarterly results put Non-Current Assets at $624.8 million for Q4 2025, up 84.04% from a year ago — trailing twelve months through Dec 2025 was $2.0 billion (down 5.7% YoY), and the annual figure for FY2025 was $624.8 million, up 84.04%.
  • Non-Current Assets for Q4 2025 was $624.8 million at Ptc Therapeutics, down from $635.9 million in the prior quarter.
  • Over the last five years, Non-Current Assets for PTCT hit a ceiling of $1.1 billion in Q2 2022 and a floor of $339.0 million in Q1 2025.
  • Median Non-Current Assets over the past 5 years was $734.0 million (2023), compared with a mean of $767.4 million.
  • Biggest five-year swings in Non-Current Assets: tumbled 49.86% in 2024 and later skyrocketed 84.04% in 2025.
  • Ptc Therapeutics' Non-Current Assets stood at $983.7 million in 2021, then rose by 2.86% to $1.0 billion in 2022, then crashed by 33.08% to $677.1 million in 2023, then tumbled by 49.86% to $339.5 million in 2024, then surged by 84.04% to $624.8 million in 2025.
  • The last three reported values for Non-Current Assets were $624.8 million (Q4 2025), $635.9 million (Q3 2025), and $361.3 million (Q2 2025) per Business Quant data.